studies

lung cancer : non small cell (NSCLC), gene alteration target therapy vs. platinum association, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsAURA3, 2017 0.87 [0.64; 1.18] 0.87[0.64; 1.18]AURA3, 201710%419NAnot evaluable progression or deaths (PFS)detailed resultsAURA3, 2017 0.30 [0.22; 0.40] 0.30[0.22; 0.40]AURA3, 201710%419NAnot evaluable DCRdetailed resultsAURA3, 2017 3.85 [2.18; 6.82] 3.85[2.18; 6.82]AURA3, 201710%419NAnot evaluable objective responses (ORR)detailed resultsAURA3, 2017 5.39 [3.45; 8.43] 5.39[3.45; 8.43]AURA3, 201710%419NAnot evaluable AE (any grade)detailed resultsAURA3, 2017 0.34 [0.04; 2.83] 0.34[0.04; 2.83]AURA3, 201710%415NAnot evaluable AE (grade 3-4)detailed resultsAURA3, 2017 0.31 [0.20; 0.48] 0.31[0.20; 0.48]AURA3, 201710%415NAnot evaluable AE leading to death (grade 5)detailed resultsAURA3, 2017 1.96 [0.22; 17.74] 1.96[0.22; 17.74]AURA3, 201710%415NAnot evaluable TRAE (any grade)detailed resultsAURA3, 2017 0.60 [0.32; 1.11] 0.60[0.32; 1.11]AURA3, 201710%415NAnot evaluable TRAE (grade 3-4)detailed resultsAURA3, 2017 0.12 [0.06; 0.22] 0.12[0.06; 0.22]AURA3, 201710%415NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-30 21:46 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 1413,435,434,1514,1515,474,1513,1390,714,423,424,425,562,426,1472,1400,1396,1468,431,1392,1391,1415,1416,1417,1493,1397,1383,1399,1426,1398,1387,1106,1108,1107,1393,1394,1402,1388,1389,1386,1384,1522,1385,1512,1511,1454

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons